What exactly was the “patent extension” for tigecycline?
Tigecycline’s patent term was extended through regulatory patent term restoration and exclusivity mechanisms tied to its development and approval timeline, which can shift the effective end date of patent protection beyond the original filing expiry. Patent term restoration is generally granted to compensate for time lost during regulatory review, but the availability and outcome depend on country-specific patent and regulatory histories.
How does regulatory review delay create patent term restoration?
For antibiotics and other drugs, the biggest driver behind a term extension is the length of the time between patent filing and marketing authorization. If regulators took years to review the product, patent term restoration can add back part of that delay to the patent term, effectively extending the period in which the sponsor can rely on patent protection. This is the most common pathway by which “patent extension” happens for marketed medicines, including tigecycline in jurisdictions that allow restoration tied to regulatory approval milestones.
Why would tigecycline’s approval timeline matter specifically?
Tigecycline’s development program and the length of clinical/regulatory steps can affect how much restoration/exclusivity is granted. If the approval process (including evidence generation and regulatory assessment) consumed a larger share of the original patent life, the restored portion—and therefore the practical extension—tends to be larger. In practice, the extension reflects: when the relevant patents were filed, when the marketing authorization was granted, and what portion of time is eligible for restoration under local rules.
What other factors besides regulatory delay can influence an “extension”?
Depending on the country, an apparent extension can come from several legal or regulatory levers, such as:
- multiple patents covering different aspects (composition, formulation, method of use) that expire on different dates, creating a longer period of market exclusivity even if one patent is earlier;
- supplementary protection mechanisms that are separate from traditional patent term (for example, exclusivity tied to authorization rather than patent scope);
- later approvals or label changes that trigger new regulatory events relevant to exclusivity/patent linkage.
Did litigation or “evergreening” play a role?
Patent extensions for branded drugs can also be influenced by patent strategy and legal challenges, including disputes over patent scope and validity. However, the underlying basis for a formal extension label typically still traces back to the regulatory framework in the relevant country (e.g., patent term restoration rules) rather than marketing strategy alone.
What you need to pinpoint to answer precisely for tigecycline
To state the exact factors for tigecycline’s extension in a specific jurisdiction, you have to identify:
1. the country where the extension occurred;
2. which patent(s) were extended/restored;
3. the legal mechanism used (patent term restoration vs exclusivity vs supplementary protection);
4. the key dates (patent filing, regulatory submission, marketing authorization grant, expiration before/after restoration).
If you tell me which country (e.g., US, EU/EP, UK, etc.) and (if known) which patent number or the cited “extension” reference you’re looking at, I can map the factors to the specific timeline and mechanism.
Sources
No sources were provided with your prompt, so I can’t cite specific documents or dates for tigecycline’s patent extension.